定坤丹治疗轻中度子宫内膜异位症盆腔疼痛的疗效评价
|
摘要
目的评价定坤丹治疗轻中度子宫内膜异位症盆腔疼痛的临床疗效。方法选取2017年6月—2018年6月在天水市第四人民医院妇科就诊的轻中度子宫内膜异位症盆腔疼痛患者70例,按随机区组法分为研究组和对照组,每组各35例,研究组给予定坤丹治疗,对照组给予期待疗法,可给予非甾体消炎药处理疼痛。两组患者治疗3个月,比较治疗前后临床症状、血清糖类抗原125(CA125)和前列腺素F2α(PGF2α)水平改变情况。结果研究组治疗后疼痛症状评分、中医症状评分、血清CA125和PGF2α水平较治疗前均明显下降(P<0.05);对照组治疗前后疼痛症状评分、中医症状评分、血清CA125和PGF2α水平变化无显著差异(P>0.05);研究组治疗后疼痛症状评分、中医证候积分、血清CA125和PGF2α水平显著低于对照组(P<0.05)。结论定坤丹能够减轻轻中度子宫内膜异位症盆腔疼痛患者的临床症状,降低患者血清CA125和PGF2α水平,对治疗轻中度子宫内膜异位症盆腔疼痛具有临床应用价值。
OBJECTIVE To evaluate the clinical efficacy of Dingkundan in the treatment of pelvic pain in mild to moderate endometriosis.METHODS 70 patients with mild to moderate pelvic pain from June 2017 to June 2018 in gynecology department of the Fourth People's Hospital of Tianshui were randomly divided into two groups,with 35 cases in each group. The study group were treated with Dingkundan while the control group were treated with expectant treatment,and non-steroid antiinflammatory drug were given to deal with pain. The clinical symptoms,the clinical symptoms,serum carbohydrate antigen 125(CA125)and prostaglandin F2α(PGF2α)were compared before and after treatment. RESULTS After treatment,the scores of pain symptoms,TCM syndromes,serum CA125 and PGF2αin the study group were significantly lower than those before treatment(P<0.05). There were no significant differences in the scores of pain symptoms,TCM syndromes,serum CA125 and PGF2αin the control group(P>0.05). The scores of pain symptoms,TCM syndromes,serum CA125 and PGF2α in the study group were compared between the two groups after treatmentwas significantly lower than the control group(P<0.05). CONCLUSION Dingkundan could alleviate the clinical symptoms and reduce the levels of serum CA125 and PGF2αin patients with mild to moderate EMS. It had clinical value in the treatment of pelvic pain in mild to moderate endometriosis.
OBJECTIVE To evaluate the clinical efficacy of Dingkundan in the treatment of pelvic pain in mild to moderate endometriosis.METHODS 70 patients with mild to moderate pelvic pain from June 2017 to June 2018 in gynecology department of the Fourth People's Hospital of Tianshui were randomly divided into two groups,with 35 cases in each group. The study group were treated with Dingkundan while the control group were treated with expectant treatment,and non-steroid antiinflammatory drug were given to deal with pain. The clinical symptoms,the clinical symptoms,serum carbohydrate antigen 125(CA125)and prostaglandin F2α(PGF2α)were compared before and after treatment. RESULTS After treatment,the scores of pain symptoms,TCM syndromes,serum CA125 and PGF2αin the study group were significantly lower than those before treatment(P<0.05). There were no significant differences in the scores of pain symptoms,TCM syndromes,serum CA125 and PGF2αin the control group(P>0.05). The scores of pain symptoms,TCM syndromes,serum CA125 and PGF2α in the study group were compared between the two groups after treatmentwas significantly lower than the control group(P<0.05). CONCLUSION Dingkundan could alleviate the clinical symptoms and reduce the levels of serum CA125 and PGF2αin patients with mild to moderate EMS. It had clinical value in the treatment of pelvic pain in mild to moderate endometriosis.
引文
[1]SUCHY T,STEPAN J.Extragenital endometriosis as a subject of interest for the surgeon[J].Rozhlchir,2004,83(5):239-241.
[2]SHIRVANI M,TABARI N M,ALIPOUR A.The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea:a randomized clinical trial[J].Arch gynecolobstet,2015,291(6):1277-1281.
[3]宋楠,冷金花.子宫内膜异位症疼痛的治疗进展[J].广东医学,2008,29(5):706-708.
[4]黄益于.原发性痛经患者外周血细胞因子和PGF2α的变化及临床意义[J].中国医学创新,2015(12):11-14.
[5]许丽芬,韩冰.活血化瘀、软坚散结法(妇痛宁)对子宫内膜异位症神经内分泌影响的实验研究[J].天津中医,2002,19(1):61-62.
[6]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊断与治疗规范[J].中华妇产科杂志,2007,42(9):645-647.
[7]杨爱萍,陈群.原发性痛经患者瘀血舌象与血小板活化因子及血小板活化因子乙酰水解酶关系[J].中国中西医结合杂志,2011(3):331-333.
[8]马民.血瘀证形成的微观机理研究[D].济南:山东中医药大学,2003.
[9]陈燕霞,马堃.定坤丹临床应用的系统评价[J].中国中药杂志,2015(20):3916-3919.
[10]郁琳,石燕.定坤丹治疗子宫内膜异位症的药理作用与机制[J].中华生殖与避孕杂志,2016,36(12):963-970.
[2]SHIRVANI M,TABARI N M,ALIPOUR A.The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea:a randomized clinical trial[J].Arch gynecolobstet,2015,291(6):1277-1281.
[3]宋楠,冷金花.子宫内膜异位症疼痛的治疗进展[J].广东医学,2008,29(5):706-708.
[4]黄益于.原发性痛经患者外周血细胞因子和PGF2α的变化及临床意义[J].中国医学创新,2015(12):11-14.
[5]许丽芬,韩冰.活血化瘀、软坚散结法(妇痛宁)对子宫内膜异位症神经内分泌影响的实验研究[J].天津中医,2002,19(1):61-62.
[6]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊断与治疗规范[J].中华妇产科杂志,2007,42(9):645-647.
[7]杨爱萍,陈群.原发性痛经患者瘀血舌象与血小板活化因子及血小板活化因子乙酰水解酶关系[J].中国中西医结合杂志,2011(3):331-333.
[8]马民.血瘀证形成的微观机理研究[D].济南:山东中医药大学,2003.
[9]陈燕霞,马堃.定坤丹临床应用的系统评价[J].中国中药杂志,2015(20):3916-3919.
[10]郁琳,石燕.定坤丹治疗子宫内膜异位症的药理作用与机制[J].中华生殖与避孕杂志,2016,36(12):963-970.